Sökning: WFRF:(Goplen Dorota)
> (2021) >
Benefit of pazopani...
-
Eriksson, MikaelLund University,Lunds universitet,Medicinsk onkologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Medical oncology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Skåne University Hospital
(författare)
Benefit of pazopanib in advanced gastrointestinal stromal tumours: results from a phase II trial (SSG XXI, PAGIST)
- Artikel/kapitelEngelska2021
Förlag, utgivningsår, omfång ...
Nummerbeteckningar
-
LIBRIS-ID:oai:lup.lub.lu.se:49677f24-9e59-4901-b5d7-78836dda6259
-
https://lup.lub.lu.se/record/49677f24-9e59-4901-b5d7-78836dda6259URI
-
https://doi.org/10.1016/j.esmoop.2021.100217DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:147817423URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:art swepub-publicationtype
-
Ämneskategori:ref swepub-contenttype
Anmärkningar
-
BACKGROUND: Patients with advanced gastrointestinal stromal tumours (GISTs) resistant to the tyrosine kinase inhibitors imatinib and sunitinib may be treated with regorafenib, which resulted in a median progression-free survival (PFS) of 4.8 months in the GRID trial. Also, pazopanib, another tyrosine kinase inhibitor, has been studied in a randomized, placebo-controlled trial (PAZOGIST) in the third line, which showed a PFS of 45.2% 4 months after study entry, but patients intolerant to sunitinib were also included. We designed another trial evaluating pazopanib, enrolling only patients with progression on both imatinib and sunitinib. PATIENTS AND METHODS: Since all eligible patients had progressive disease, we preferred a non-randomized, phase II multicentre trial so that all patients could receive a potentially active drug. Patients had a progressive metastatic or locally advanced GIST and were ≥18 years of age, with a performance status of 0-2, and sufficient organ functions. The primary endpoint was disease control rate (defined as complete remission + partial remission + stable disease) at 12 weeks on pazopanib. A Simon's two-stage analysis was used with an interim analysis 12 weeks after enrollment of the first 22 patients, and if passed, there was a full enrolment of 72 patients. GIST mutational analysis was done, and most patients had pazopanib plasma concentration measured after 12 weeks. RESULTS: Seventy-two patients were enrolled. The disease control rate after 12 weeks was 44%, and the median PFS was 19.6 weeks (95% confidence interval 12.6-23.4 weeks). Pazopanib-related toxicity was moderate and manageable. No statistically significant differences were found related to mutations. Plasma concentrations of pazopanib had a formal but weak correlation with outcome. CONCLUSION: Pazopanib given in the third line to patients with GIST progressing on both imatinib and sunitinib was beneficial for about half of the patients. The PAGIST trial confirms the results from the PAZOGIST trial, and the median PFS achieved seems comparable to the PFS achieved with regorafenib in the third-line setting.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Reichardt, P.HELIOS Klinikum Berlin-Buch
(författare)
-
Joensuu, HHelsinki University Central Hospital
(författare)
-
Krarup-Hansen, A.Herlev Hospital
(författare)
-
Hagberg, OskarLund University,Lunds universitet,Urologi - blåscancer, Malmö,Forskargrupper vid Lunds universitet,Urology - urothelial cancer, Malmö,Lund University Research Groups(Swepub:lu)mats-oha
(författare)
-
Hohenberger, P.Heidelberg University
(författare)
-
Hagberg, HUppsala University Hospital
(författare)
-
Hansson, LSahlgrenska Academy
(författare)
-
Foukakis, TheodorosKarolinska Institutet
(författare)
-
Pulkkanen, K.Kuopio University Hospital
(författare)
-
Bauer, S.University of Duisburg-Essen
(författare)
-
Goplen, DorotaHaukeland University Hospital
(författare)
-
Blach-Rossen, P.Aarhus University Hospital
(författare)
-
Sundby Hall, KirstenNorwegian Radium Hospital,Oslo university hospital
(författare)
-
Medicinsk onkologiSektion I
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:ESMO Open: Elsevier BV6:42059-7029
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Eriksson, Mikael
-
Reichardt, P.
-
Joensuu, H
-
Krarup-Hansen, A ...
-
Hagberg, Oskar
-
Hohenberger, P.
-
visa fler...
-
Hagberg, H
-
Hansson, L
-
Foukakis, Theodo ...
-
Pulkkanen, K.
-
Bauer, S.
-
Goplen, Dorota
-
Blach-Rossen, P.
-
Sundby Hall, Kir ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
ESMO Open
- Av lärosätet
-
Lunds universitet
-
Karolinska Institutet